Harbor Asset Planning Inc. Takes Position in iShares U.S. Pharmaceuticals ETF $IHE

Harbor Asset Planning Inc. acquired a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the second quarter, Holdings Channel.com reports. The fund acquired 412 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors have also modified their holdings of the company. Arlington Trust Co LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the first quarter valued at $32,000. Garde Capital Inc. purchased a new position in iShares U.S. Pharmaceuticals ETF in the first quarter valued at $46,000. Wayfinding Financial LLC purchased a new position in iShares U.S. Pharmaceuticals ETF in the first quarter valued at $47,000. IFP Advisors Inc boosted its holdings in iShares U.S. Pharmaceuticals ETF by 231.2% in the first quarter. IFP Advisors Inc now owns 944 shares of the company’s stock valued at $67,000 after purchasing an additional 659 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in iShares U.S. Pharmaceuticals ETF by 20.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the company’s stock valued at $90,000 after purchasing an additional 216 shares during the period.

iShares U.S. Pharmaceuticals ETF Trading Up 0.1%

NYSEARCA:IHE opened at $74.29 on Friday. The firm has a market cap of $598.03 million, a PE ratio of 17.75 and a beta of 0.70. The stock has a fifty day moving average price of $71.49 and a 200 day moving average price of $67.66. iShares U.S. Pharmaceuticals ETF has a 12-month low of $58.97 and a 12-month high of $76.14.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.